Superluminal Medicines raises $60M Series B for Phase 1 trials of MC4R obesity drug, backed by investors including Eli Lilly, RA Capital and Nvidia's VC arm.
Cony D'Cruz, Superluminal CEO
September 3, 2026 06:00 AM EDTUpdated 09:26 AM
FinancingStartups
Superluminal secures $60M for Phase 1 of genetic obesity drug
Kyle LaHucik
Superluminal Medicines banked $60 million in funding to support development of a drug designed to work similarly to — but…
The anti-aging biotech has secured one of the year’s biggest venture fundings to bring its first drug into testing. Elsewhere,…
Newly published data convinced AstraZeneca to conduct a sprawling late-stage program for its GLP-1 pill. Elsewhere, Bausch + Lomb…
A next-gen Eli Lilly obesity drug led to bariatric-surgery levels of weight loss in a study, but also saw patients dropping out…
After a lengthy downturn, the biotech industry finally gathered momentum in 2025. Key readouts in obesity, infectious disease and…
Longevity startup NewLimit plans to launch its first clinical trial of a liver medicine after raising a staggering $435 million…
